FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3081364008> ?p ?o ?g. }

• W3081364008 endingPage "1308" @default.
• W3081364008 startingPage "1297" @default.
• W3081364008 abstract "The epidemic due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been spreading globally, raising increasing concerns. There are several controversial hypotheses on the potentially harmful or beneficial effects of antihypertensive drugs acting on the renin–angiotensin–aldosterone system (RAAS) in coronavirus disease 2019 (COVID-19). Furthermore, there is accumulating evidence, based on several observational studies, that angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) do not increase the risk of contracting SARS-CoV-2 infection. On the other hand, conflicting findings regarding the role of ACEIs/ARBs as prognosis modifiers in COVID-19 hospitalised patients have been reported. The aim of this large-scale, retrospective cohort study was to investigate whether prior exposure to ACEIs and/or ARBs was associated with all-cause mortality among over 40,000 hospitalised COVID-19 patients compared with calcium channel blockers (CCBs), a potential therapeutic alternative. This study was conducted using COVID-19 registries linked to claims databases from Lombardy, Veneto and Reggio Emilia (overall, 25% of Italian population). Overall, 42,926 patients hospitalised between 21 February and 21 April 2020 with a diagnosis of COVID-19 confirmed by real-time polymerase chain reaction tests were included in this study. All-cause mortality occurring in or out of hospital, as reported in the COVID-19 registry, was estimated. Using Cox models, adjusted hazard ratios (HRs) of all-cause mortality (along with 95% confidence intervals [CIs]) were estimated separately for ACEIs/ARBs and other antihypertensives versus CCBs and non-use. Overall, 11,205 in- and out-of-hospital deaths occurred over a median of 24 days of follow-up after hospital admission due to COVID-19. Compared with CCBs, adjusted analyses showed no difference in the risk of death among ACEI (HR 0.97, 95% CI 0.89–1.06) or ARB (HR 0.98, 95% CI 0.89–1.06) users. When non-use of antihypertensives was considered as a comparator, a modest statistically significant increase in mortality risk was observed for any antihypertensive use. However, when restricting to drugs with antihypertensive indications only, these marginal increases disappeared. Sensitivity and subgroup analyses confirmed our main findings. ACEI/ARB use is not associated with either an increased or decreased risk of all-cause mortality, compared with CCB use, in the largest cohort of hospitalised COVID-19 patients exposed to these drugs studied to date. The use of these drugs therefore does not affect the prognosis of COVID-19. This finding strengthens recommendations of international regulatory agencies about not withdrawing/switching ACEI/ARB treatments to modify COVID-19 prognosis." @default.
• W3081364008 created "2020-09-01" @default.
• W3081364008 creator A5001627390 @default.
• W3081364008 creator A5005612531 @default.
• W3081364008 creator A5009914520 @default.
• W3081364008 creator A5012784095 @default.
• W3081364008 creator A5020503685 @default.
• W3081364008 creator A5020775499 @default.
• W3081364008 creator A5024916387 @default.
• W3081364008 creator A5039807679 @default.
• W3081364008 creator A5044282024 @default.
• W3081364008 creator A5044521054 @default.
• W3081364008 creator A5045367285 @default.
• W3081364008 creator A5046647232 @default.
• W3081364008 creator A5048795508 @default.
• W3081364008 creator A5061070734 @default.
• W3081364008 creator A5061665466 @default.
• W3081364008 creator A5063403768 @default.
• W3081364008 creator A5072672818 @default.
• W3081364008 creator A5074587986 @default.
• W3081364008 creator A5075358428 @default.
• W3081364008 creator A5077215884 @default.
• W3081364008 creator A5079770254 @default.
• W3081364008 creator A5084494048 @default.
• W3081364008 creator A5085896025 @default.
• W3081364008 date "2020-08-27" @default.
• W3081364008 modified "2023-10-17" @default.
• W3081364008 title "Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients" @default.
• W3081364008 cites W1964982019 @default.
• W3081364008 cites W2028521865 @default.
• W3081364008 cites W2083695720 @default.
• W3081364008 cites W2091671824 @default.
• W3081364008 cites W2893311239 @default.
• W3081364008 cites W3009723094 @default.
• W3081364008 cites W3009912996 @default.
• W3081364008 cites W3009976289 @default.
• W3081364008 cites W3010580363 @default.
• W3081364008 cites W3013871850 @default.
• W3081364008 cites W3015407900 @default.
• W3081364008 cites W3016572296 @default.
• W3081364008 cites W3017545174 @default.
• W3081364008 cites W3019844653 @default.
• W3081364008 cites W3021366174 @default.
• W3081364008 cites W3023640683 @default.
• W3081364008 cites W3023751598 @default.
• W3081364008 cites W3023826646 @default.
• W3081364008 cites W3024575398 @default.
• W3081364008 cites W3025099648 @default.
• W3081364008 cites W3028972713 @default.
• W3081364008 cites W3031384430 @default.
• W3081364008 cites W3032939692 @default.
• W3081364008 cites W3035819488 @default.
• W3081364008 cites W3036441990 @default.
• W3081364008 cites W3036500066 @default.
• W3081364008 cites W3040730385 @default.
• W3081364008 doi "https://doi.org/10.1007/s40264-020-00994-5" @default.
• W3081364008 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7450482" @default.
• W3081364008 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32852721" @default.
• W3081364008 hasPublicationYear "2020" @default.
• W3081364008 type Work @default.
• W3081364008 sameAs 3081364008 @default.
• W3081364008 citedByCount "42" @default.
• W3081364008 countsByYear W30813640082020 @default.
• W3081364008 countsByYear W30813640082021 @default.
• W3081364008 countsByYear W30813640082022 @default.
• W3081364008 countsByYear W30813640082023 @default.
• W3081364008 crossrefType "journal-article" @default.
• W3081364008 hasAuthorship W3081364008A5001627390 @default.
• W3081364008 hasAuthorship W3081364008A5005612531 @default.
• W3081364008 hasAuthorship W3081364008A5009914520 @default.
• W3081364008 hasAuthorship W3081364008A5012784095 @default.
• W3081364008 hasAuthorship W3081364008A5020503685 @default.
• W3081364008 hasAuthorship W3081364008A5020775499 @default.
• W3081364008 hasAuthorship W3081364008A5024916387 @default.
• W3081364008 hasAuthorship W3081364008A5039807679 @default.
• W3081364008 hasAuthorship W3081364008A5044282024 @default.
• W3081364008 hasAuthorship W3081364008A5044521054 @default.
• W3081364008 hasAuthorship W3081364008A5045367285 @default.
• W3081364008 hasAuthorship W3081364008A5046647232 @default.
• W3081364008 hasAuthorship W3081364008A5048795508 @default.
• W3081364008 hasAuthorship W3081364008A5061070734 @default.
• W3081364008 hasAuthorship W3081364008A5061665466 @default.
• W3081364008 hasAuthorship W3081364008A5063403768 @default.
• W3081364008 hasAuthorship W3081364008A5072672818 @default.
• W3081364008 hasAuthorship W3081364008A5074587986 @default.
• W3081364008 hasAuthorship W3081364008A5075358428 @default.
• W3081364008 hasAuthorship W3081364008A5077215884 @default.
• W3081364008 hasAuthorship W3081364008A5079770254 @default.
• W3081364008 hasAuthorship W3081364008A5084494048 @default.
• W3081364008 hasAuthorship W3081364008A5085896025 @default.
• W3081364008 hasBestOaLocation W30813640081 @default.
• W3081364008 hasConcept C126322002 @default.
• W3081364008 hasConcept C167135981 @default.
• W3081364008 hasConcept C198710026 @default.
• W3081364008 hasConcept C201903717 @default.
• W3081364008 hasConcept C207103383 @default.
• W3081364008 hasConcept C2908647359 @default.
• W3081364008 hasConcept C44249647 @default.

• next